The peptide directs the conjugate to receptors overexpressed in tumors, such as carbonic anhydrase IX (CAIX) or VEGFR in renal cell carcinoma (RCC), while the linker ensures stable circulation and controlled drug release within the tumor microenvironment. Here, KDR is linked to renal cell carcinoma.